Glycomine Inc.

📍 San Carlos, United States👥 23 employees💰 Last funded Apr 2025
Biotechnology Research🌐 glycomine.com
Website LinkedIn
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The companys approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Canada
1
Investor activity2016–2025 · investors recorded per year
201612021120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Glycomine Inc.?
Glycomine Inc. has 3 investors on record on gritt.io.
When did Glycomine Inc. last raise funding?
The most recent investment in Glycomine Inc. recorded on gritt.io was in April 2025.
What industry is Glycomine Inc. in?
Glycomine Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Glycomine Inc. based?
Glycomine Inc. is headquartered in San Carlos, United States.